Comment by gavinray
1 day ago
To offer context for others:
The bigger deal about this is that KRAS was considered an "undruggable" target.
Recent advancements have allowed us to design biologics to do things we previously thought impossible, which broadens the horizons for other treatments in the future.
Baby steps.
What's next then?
The Johns Hopkins Children's' Center is looking at trialing it for rhabdomyosarcoma, a particularly deadly form of cancer that primary targets children. If successful, this would represent a HUGE leap forward in its treatment.
Other cancers, obesity, name it.